logo
33-year-old given months to live after ‘long Covid' turned out to be leukaemia says doctor asked her about Dignitas

33-year-old given months to live after ‘long Covid' turned out to be leukaemia says doctor asked her about Dignitas

Yahoo07-04-2025
An athletic 33-year-old given months to live after her leukaemia was initially mistaken for long Covid has said one doctor asked if she had considered Dignitas, amid a series of devastating relapses. Olivia Knowles started experiencing headaches and tiredness in late 2023 and was told it was "very likely long Covid", before extreme toothache days later prompted an emergency hospital visit and a diagnosis of acute myeloid leukaemia (AML).
After a series of relapses and months of attempted cures over the course of 2024, including gruelling chemotherapy, Olivia said at one stage a doctor asked if she would consider "taking a flight" to the assisted dying centre Dignitas in Switzerland. She received a stem cell transplant in December 2024 and months later was declared cancer-free – but just a week later, in early March this year, Olivia was given the "bitter" news the leukaemia had returned and she now had months to live.
The hair salon owner from Blackpool, whose "typical weekend" before her diagnosis involved 100-mile bike rides and 15-mile runs, walked 20 miles around Fairhaven Lake on March 16 to raise funds for clinical research at King's College Hospital. She said she hopes any donations will improve research on AML, a particularly aggressive cancer which, she said, has not seen any "solid advancements" in treatment for 50 years.
READ MORE: Half a million Brits to lose access to free dental work or prescriptions 'within days'
READ MORE: NHS warning as Covid cases jump to 'highest level of 2025'
"I always thought that relapse would be a real possibility, but obviously, I just didn't expect it to be so soon," Olivia told PA Real Life. "All I really miss now is going to work and training. That's all I want – just my normal day and my normal routine.
"If you could have one day, it might sound odd to some people, but I would just love to take the dog for a run and go to work, more than anything." Olivia started noticing something "wasn't quite correct" in August 2023 while competing in the Half Ironman World Championship in Lahti, Finland.
The two-mile swim and 56-mile cycle went smoothly, she said, but the 13-mile run to the finish line "quickly turned into a 'let's just get round this'".
"I just wasn't able to push as hard as I normally would have been able to," she said. "But I didn't feel unwell day to day, so I was just pushing it to the back of my mind."
Olivia went to a private doctor in November 2023 but was told it was "very likely to be long Covid" and she should "expect to feel like this for some time". Two days later, she was admitted to Blackpool A&E with extreme toothache and sepsis and was told soon after she had an aggressive form of acute myeloid leukaemia that responds poorly to treatment.
"It was a total shock," she said. "I'm not saying I was the healthiest person in the world, but I was quite healthy – I didn't have a lifestyle that was indicative of cancer."
Olivia began a regime of chemotherapy designed to "completely empty" her bone marrow to see whether the cancerous cells grew back. This procedure stripped away her immune system, leaving her extremely vulnerable to infection and unable to leave hospital.
"I went to hospital on November 7 and I didn't leave until Christmas Eve," Olivia recalled. Following two rounds of chemo with varying degrees of success, Olivia's third treatment in April 2024 largely succeeded in eradicating her leukaemia.
But just before she was due to have a stem cell transplant to replace her bone marrow, a pre-surgery appointment was moved unexpectedly.
"I thought that seemed strange, so I went down to the hospital and asked to speak to my consultant," she said. "It became a very weird scenario in which he wouldn't come on the phone to speak to my nurse specialist, or me. I ended up speaking to him the day after, and obviously I'd relapsed."
With AML, Olivia explained: "Even if there's a speck of it left, it just regrows. And what regrows is basically the resistant cells, the ones that have evaded and resisted the previous chemo."
Olivia's consultant at Blackpool Victoria Hospital gave her three options – try to get a transplant despite her relapse, join a clinical trial, or "do nothing". Olivia said a consultant offering a second opinion at another hospital asked her: "Have you ever thought about taking a flight?"
This confused her because AML patients are advised to avoid "anywhere where the air is recirculated", such as on planes, but "then the penny dropped, and I realised he'd suggested going to Dignitas (the Swiss assisted dying clinic)". In November 2024, after various unsuccessful trials, Olivia was given a novel Car-T treatment – immunotherapy which genetically modifies a patient's T-cells to attack cancer.
The treatment at King's College Hospital in London was followed by a stem cell transplant.
"The initial bone marrow findings were excellent," she said. "There were no signs of disease. It was a really positive result at first. I was feeling probably the best I'd felt for quite some time."
In March 2025, Olivia was readmitted with gut issues, a common side effect of stem cell transplants. She said: "I'd been in for blood literally one week before. The blood work had been very good, no reason for concern. One week later, I showed active disease. My counts were off."
Olivia said her consultant was "blindsided" by her relapse, because the transplant had gone so well.
"When I got the news, I wanted to go home," she said. "It was a bitter pill to swallow after being told there's no disease."
While home with her mum Susan and dad Stephen, Olivia decided "on a little bit of a whim" to walk a marathon around Fairhaven Lake to raise funds for the clinical research team at King's. The former triathlete was forced to stop after 20 miles but still raised more than £25,000.
She said: "It went exactly how I expected it to go, because my legs have atrophied so much." She hopes the money will contribute to "solid advancements", saying the team at King's "are on the cusp of something excellent with their development of Car-T treatment for AML".
"For them to have something that can help treat children, it gives you a bit more hope," she said. Olivia began a new chemo regime in late March, with the intention of joining another clinical trial.
Reflecting on her treatment, she said: "We did almost do it, but 'almost' doesn't matter. I did this (walk) so one day the next 33-year-old, the next one-year-old, the next one-month-old, isn't an 'almost'." Olivia's fundraiser remains open, and can be found at: gofundme.com/f/kings-college-hospital-clinical-research-department.
Looking for more from MyLondon? Subscribe to our daily newsletters here for the latest and greatest updates from across London.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

21 state AG's ask feds to ban 'designer Xanax' after Kentucky ban
21 state AG's ask feds to ban 'designer Xanax' after Kentucky ban

UPI

time17 minutes ago

  • UPI

21 state AG's ask feds to ban 'designer Xanax' after Kentucky ban

1 of 2 | "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," two-term Democratic Gov. Andy Beshear (pictured at the August 2024 DNC in Chicago, Ill.) said Monday. File Photo by Tannen Maury/UPI | License Photo Aug. 19 (UPI) -- Kentucky designated "bromazolam" as a Schedule 1 controlled substance as Gov. Andy Beshear also led a push to have it designated similarly at the federal level. Beshear announced the effort to ban the drug, also known as "designer Xanax" Monday after bromazolam was detected in at least 48 overdose deaths in Kentucky last year. "This deadly drug has no place in our communities, and now we have the tools needed to get it off the streets and protect more lives," the two-term Democratic governor said in a statement. The governor's signature immediately banned the drug from being sold in Kentucky and empowered law enforcement to act and arrest for sales or possession. It also provides further tools for authorities in Beshear's statewide crackdown. A 2021 report suggested that overdose deaths linked to illicit "designer" drugs had surged in the United States a staggering 520% between 2019 and 2020 during the COVID-19 pandemic, according to data from 32 states and the District of Columbia. On Monday, the rumored Democratic presidential candidate pointed to "important progress" in Kentucky's fight against addiction with three straight years of declines in overdose deaths. "And we're committed to ensuring that work continues," Beshear added. Beshear's executive action this week reportedly came following a request by the state's Republican Attorney General Russell Coleman. "We live in a moment when as little as one pill can kill -- and is killing -- our kids," Coleman said Monday in a joint statement with Beshear. "I'm glad we could work together to tackle this grave threat," he added on the bipartisan effort to rid the streets of the "designer" bromazolam. In 1985 the federal government enacted its ban on the so-called "designer drug" Ecstasy entirely due to the fact it was created by chemists and Ecstasy spin-offs were starting to hit the streets. Coleman and 20 other GOP state attorneys general are now calling on the federal government to follow state actions. "Despite its clear dangers, bromazolam remains unscheduled at the federal level, creating significant challenges for law enforcement and public health officials trying to respond to this emerging crisis," read a letter in part to DEA Administrator Terry Cole signed by Coleman and Alabama's Attorney General Steve Marshall, Tim Griffin in Arkansas, Florida's James Uthmeier, Georgia Attorney General Chris Carr, Indiana's Attorney General Todd Rokita and Brenna Bird from Iowa, Liz Murrill of Louisiana, Lynn Fitch of Mississippi, Montana's Austin Knudsen, Mike Hilgers of Nebraska, Drew Wrigley of North Dakota, Dave Yost of Ohio, Oklahoma's Gentner Drummond, Pennsylvania's new Attorney General Dave Sunday, Alan Wilson of South Carolina, Marty Jackley of South Dakota, Jonathan Skrmetti of Tennessee, Virgina's Jason Miyares, John 'JB' McCuskey of West Virginia and Ken Paxton of Texas. Coleman's letter pointed to how the originally synthesized but never approved for medical use bromazolam is now being illegally sold on the streets and in online platforms. The band of Republican state chief law enforcement officers argues that without its scheduling on a federal level, bromazolam will continue to "evade traditional regulatory and prosecutorial tools," which they added will hinder interdiction efforts and enable "continued distribution through illicit channels." "Virginia took proactive action by scheduling bromazolam," Virginia's Attorney General Jason Miyares said Monday. "Now, I'm encouraging federal action to ensure every state has the same tools to protect Americans," the Republican AG and first Latino elected to statewide office in Virginia posted on social media.

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Yahoo

time23 minutes ago

  • Yahoo

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Leading pediatric group breaks with RFK Jr., recommends COVID shots for young kids
Leading pediatric group breaks with RFK Jr., recommends COVID shots for young kids

The Hill

timean hour ago

  • The Hill

Leading pediatric group breaks with RFK Jr., recommends COVID shots for young kids

The American Academy of Pediatrics (AAP) on Tuesday recommended that parents vaccinate all infants and young children against COVID-19, a break from Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and his criticism of widespread vaccination. The group recommended all infants and children 6 months through 23 months get vaccinated against COVID-19 to help protect against serious illness. Children under 2 years old are especially vulnerable to severe COVID-19 and should be prioritized for vaccination, AAP said, unless they have a known allergy to the vaccine or its ingredients. The COVID recommendations were part of AAP's broader guidance for parents and pediatricians ahead of respiratory virus season and come as medical groups fight against what they see as Kennedy's efforts to undermine childhood vaccinations, including against the coronavirus. Kennedy in May announced in a video posted on X that the Centers for Disease Control and Prevention (CDC) would no longer recommend routine COVID-19 shots for healthy children because of a lack of any clinical data to justify yearly vaccines. 'The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children and adolescents,' AAP President Susan J. Kressly said in a statement. 'Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving.' The CDC did not go as far as Kennedy wanted on COVID shots and instead recommended 'shared decision making' between parents and clinicians to decide whether a healthy child should get a shot. AAP also advised shared decision making for children ages 2-18 whose parent or guardian desires them to have the protection of the vaccine. But the Food and Drug Administration did not approve Moderna's COVID-19 vaccine for use in healthy young children, only those with a health condition that puts them at increased risk of severe illness. Since it was founded in 1930, AAP has published evidence-based vaccine guidance to support pediatricians. But it has not traditionally differed substantially from federal recommendations. AAP and HHS have been at odds for months, and tensions reached a head when Kennedy dismissed all the members of the CDC's Advisory Committee on Immunization Practices (ACIP) and replaced them with his own handpicked representatives, including some outright vaccine skeptics. AAP's recommendation 'differs from recent recommendations of the Advisory Committee on Immunization Practices of the CDC, which was overhauled this year and replaced with individuals who have a history of spreading vaccine misinformation,' the group said in a statement. AAP chose not to participate in the reconstituted panel's first meeting in June, calling it 'illegitimate.' Kennedy later excluded AAP along with other top medical organizations from working with the panel to research and help influence vaccination recommendations. For decades, ACIP recommended which shots Americans should get and when. The Affordable Care Act requires all insurance companies to cover, for free, the vaccines recommended by the panel. Those recommendations also help states decide which shots should be mandated for schoolchildren. The panel has yet to vote on COVID-19 shot recommendations. Kennedy's shake-up is throwing that system into chaos. Outside physician and public health groups have been pressuring insurance companies to continue covering vaccines, no matter what ACIP does. 'The AAP urges every insurer to cover all the vaccines that are included in this immunization schedule,' Kressly said in the statement. 'AAP is committed to working with our partners at the local, state and federal levels to make sure every child, in every community has access to vaccines.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store